Food and Drug Administration Guidance on Design of Clinical Trials for Gene Therapy Products with Potential for Genome Integration or Genome Editing and Associated Long-Term Follow-Up of Research Subjects
Applied Biosafety · 01.12.2022 · 27 (4) · 201-209
DOI: 10.1089/apb.2022.0022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Biosafety, erschienen am 01.12.2022. Verfasst von Daniel Eisenman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosafety Services, Advarra, Inc., Columbia, Maryland, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biosafety Services, Advarra, Inc., Columbia, Maryland, USA.
ORCID-Profile: Daniel Eisenman
Zitieren
APA
Eisenman, D., & Swindle, S. (2022). Food and Drug Administration Guidance on Design of Clinical Trials for Gene Therapy Products with Potential for Genome Integration or Genome Editing and Associated Long-Term Follow-Up of Research Subjects. Applied Biosafety, 27(4), 201-209. https://doi.org/10.1089/apb.2022.0022
Vancouver
Eisenman D, Swindle S. Food and Drug Administration Guidance on Design of Clinical Trials for Gene Therapy Products with Potential for Genome Integration or Genome Editing and Associated Long-Term Follow-Up of Research Subjects. Applied Biosafety. 2022;27(4):201-209. doi:10.1089/apb.2022.0022
BibTeX
@article{Eisenman2022,
author = {Eisenman, Daniel and Swindle, Scott},
title = {Food and Drug Administration Guidance on Design of Clinical Trials for Gene Therapy Products with Potential for Genome Integration or Genome Editing and Associated Long-Term Follow-Up of Research Subjects},
journal = {Applied Biosafety},
year = {2022},
volume = {27},
number = {4},
pages = {201--209},
doi = {10.1089/apb.2022.0022}
}
EUVIMED